Medical Condition News

RSS

Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting

Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Researchers identify predictive biomarker for Parkinson's disease

Because there is currently no laboratory test that can diagnose Parkinson's disease, it is practically impossible to detect those individuals who are in the earliest stages of the disease. As a result, Parkinson's disease can only be diagnosed by a clinical neurological examination based on findings suggestive of the disease.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

HCMS, ACOEM announce important expansion to Blueprint for Health

The American College of Occupational and Environmental Medicine (ACOEM) and the HCMS Group have announced an important expansion to their "Blueprint for Health" - a free internet-based calculating tool that helps employers better comprehend and analyze the impact of medical costs, absence, and work impairment among their employees.

5 Jun 2012

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

5 Jun 2012

High doses of ginseng more effectively reduce cancer-related fatigue in patients

High doses of the herb American ginseng (Panax quinquefolius) over two months reduced cancer-related fatigue in patients more effectively than a placebo, a Mayo Clinic-led study found. Sixty percent of patients studied had breast cancer. The findings are being presented at the American Society of Clinical Oncology's annual meeting.

5 Jun 2012

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Researchers at Universitat Aut-noma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the --amyloid protein, involved in Alzheimer's disease.

5 Jun 2012

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Senesco Technologies, Inc. reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

5 Jun 2012

Researchers uncover brain signaling pathway responsible for renal excretory function

Boston University School of Medicine (BUSM) researchers recently uncovered a brain signaling pathway responsible for regulating the renal excretion of sodium. The findings appear in the Journal of the Federation of American Societies for Experimental Biology.

5 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Baxter International Inc. today announced that it has entered into an exclusive global agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of potential treatments for hemophilia B utilizing Chatham's gene therapy technology.

From Baxter International Inc. 5 Jun 2012

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced positive top-line results from the IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) Phase III clinical program of XIAFLEX for the treatment of Peyronie's disease, which was conducted by BioSpecifics' partner Auxilium Pharmaceuticals, Inc.

5 Jun 2012

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

Incyte Corporation presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2012

New region on the X chromosome plays a role in migraine

New hope has arrived for migraine sufferers following a Griffith University study with the people of Norfolk Island. Led by Professor Lyn Griffiths from the University's Griffith Health Institute, the team has identified a new region on the X chromosome as playing a role in migraine.

5 Jun 2012

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA.

5 Jun 2012

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Those cups of coffee that you drink every day to keep alert appear to have an extra perk - especially if you're an older adult. A recent study monitoring the memory and thinking processes of people older than 65 found that all those with higher blood caffeine levels avoided the onset of Alzheimer's disease in the two-to-four years of study follow-up. Moreover, coffee appeared to be the major or only source of caffeine for these individuals.

5 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

New algorithm can help ED physicians to reduce number of heart failure deaths

Physicians can reduce the number of heart failure deaths and unnecessary hospital admissions by using a new computer-based algorithm developed at the Institute for Clinical Evaluative Sciences (ICES) that calculates each patient's individual risk of death. Published in the Annals of Internal Medicine, the algorithm improves upon clinical decision-making and determines whether or not a patient with heart failure should be admitted to hospital.

5 Jun 2012

Medical Condition News

Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting

Researchers identify predictive biomarker for Parkinson's disease

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

HCMS, ACOEM announce important expansion to Blueprint for Health

Alnylam announces results from ALN-VSP Phase I study on liver cancers

High doses of ginseng more effectively reduce cancer-related fatigue in patients

ASS234 molecule inhibits aggregation of the Alzheimer's protein

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Researchers uncover brain signaling pathway responsible for renal excretory function

Exelixis reports data from cabozantinib phase 3 trial on MTC

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Chatham, Baxter partner to develop and commercialize hemophilia B gene therapy treatment

Positive results from BioSpecifics’ XIAFLEX Phase III clinical program on Peyronie's disease

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

New region on the X chromosome plays a role in migraine

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

Caffeine/coffee intake associated with reduced risk of dementia or delayed onset

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

New algorithm can help ED physicians to reduce number of heart failure deaths

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News